Treatment of chronic hepatitis C with recombinant interferon alfa-2b

Gut. 1993;34(2 Suppl):S128-9. doi: 10.1136/gut.34.2_suppl.s128.

Abstract

In a study of 87 patients with chronic hepatitis C, 12 months' treatment with interferon alfa-2b at a dose of 6 million units (MU) three times per week seemed to be more effective than treatment with 3 MU three times a week for two months plus 1.5 MU three times a week for 10 months in increasing the percentage of long term responders. The percentage of patients in whom alanine amino-transferase activities returned to normal was highest in the 6 MU group, as was the percentage of responders who sustained this normal activity after treatment. Side effects were moderate and self-limited in most patients.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Alanine Transaminase / blood
  • Drug Administration Schedule
  • Female
  • Hepatitis C / enzymology
  • Hepatitis C / therapy*
  • Hepatitis, Chronic / therapy*
  • Humans
  • Injections, Intramuscular
  • Injections, Intravenous
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Male
  • Middle Aged
  • Recombinant Proteins

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Alanine Transaminase